These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience]. Míka P; Behounek J; Skoták M; Nevsímal L Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102 [TBL] [Abstract][Full Text] [Related]
7. [Focus on anticoagulants]. Montalescot G Ann Cardiol Angeiol (Paris); 1991 Dec; 40(10):603-6. PubMed ID: 1781635 [TBL] [Abstract][Full Text] [Related]
8. Pharmacology of anticoagulants. Loke C; Ali SS; Johari V Dis Mon; 2012 Aug; 58(8):424-30. PubMed ID: 22818556 [No Abstract] [Full Text] [Related]
9. [Heparins, antivitamins K. Principles and rules of use. Posology of non-fractionated heparins]. Delsart D; Chambefort V; Decousus H Rev Prat; 2001 Sep; 51(13):1489-97. PubMed ID: 11601082 [No Abstract] [Full Text] [Related]
10. Laboratory monitoring of new antithrombotic drugs. Breddin HK; Radziwon P; Boczkowska-Radziwon B Clin Lab Med; 1994 Dec; 14(4):825-46. PubMed ID: 7874874 [TBL] [Abstract][Full Text] [Related]
11. [Glycoprotein IIb/IIIa antagonists as antithrombotic agents]. Reikvam A; Madsen S Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1118-20. PubMed ID: 12043057 [No Abstract] [Full Text] [Related]
12. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Levi MM; Eerenberg E; Löwenberg E; Kamphuisen PW Neth J Med; 2010 Feb; 68(2):68-76. PubMed ID: 20167958 [TBL] [Abstract][Full Text] [Related]
13. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G; Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196 [TBL] [Abstract][Full Text] [Related]
14. Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Haas S; Walenga JM; Jeske WP; Fareed J Semin Thromb Hemost; 1999; 25 Suppl 1():67-75. PubMed ID: 10357155 [TBL] [Abstract][Full Text] [Related]
15. Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade. Durand M; Lecompte T; Hacquard M; Carteaux JP Eur J Cardiothorac Surg; 2008 Sep; 34(3):687-9. PubMed ID: 18579401 [TBL] [Abstract][Full Text] [Related]
16. Monitoring the effects and managing the side effects of anticoagulation during pregnancy. Gris JC; Lissalde-Lavigne G; Quére I; Marés P Obstet Gynecol Clin North Am; 2006 Sep; 33(3):397-411. PubMed ID: 16962917 [TBL] [Abstract][Full Text] [Related]
17. Antithrombotic drugs in vascular medicine: a historical perspective. Schrör K Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472 [TBL] [Abstract][Full Text] [Related]
18. Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system. Tiaden JD; Wenzel E; Berthold HK; Müller-Oerlinghausen B Semin Thromb Hemost; 2005; 31(4):371-80. PubMed ID: 16149013 [TBL] [Abstract][Full Text] [Related]